Search Within

Matthew J Matasar

Formats
  1. Meeting Abstract (190)
  2. Journal Article (85)
  3. Book Section (4)
  4. Review (3)
  5. Correspondence (2)
  6. Editorial (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (290)
  2. Department of Medicine (290)
  3. Hematologic Malignancies, Division of (290)
  4. Lymphoma (290)
  5. Survivorship Research (290)
  6. Population Sciences Research Program (111)

More Groups

People
  1. Andrew Zelenetz (116)
  2. David Straus (102)
  3. Ariela Noy (98)
  4. Paul Hamlin (98)
  5. Steven Horwitz (96)
  6. Alison Moskowitz (95)

More People

Years
  1. 2024 (6)
  2. 2023 (12)
  3. 2022 (43)
  4. 2021 (43)
  5. 2020 (23)
  6. 2019 (34)

More Years

Publications
  1. Blood (108)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (22)
  4. Biology of Blood and Marrow Transplantation (11)
  5. Clinical Lymphoma, Myeloma and Leukemia (11)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (118)
  2. American Society of Clinical Oncology (37)
  3. Elsevier Inc. (28)
  4. Wiley Blackwell (26)
  5. Oxford University Press (13)
  6. John Wiley & Sons (10)

More Publishers

Results (290)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polatuzumab vedotin + rituximab, cyclophosphamid, doxorubicin und prednison (Pola-R-CHP) im vergleich zu rituximab, cyclophosphamid, doxorubicin, vincristin und prednison (R-CHOP) bei patient: Innen mit unbehandeltem diffusemgroßzelligem B-zell-lymphom (DLBCL): Ergebnisse der phase III POLARIX studie
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab-monotherapie ist eine wirksame und gut verträgliche behandlungsoption bei patienten mit rezidiviertem/refraktärem follikulärem lymphom, die zuvor bereits ≥2 therapielinien erhalten haben: Wichtige ergebnisse einer phase-I/II-studie
    Meeting Abstract

    Hess, G.; Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas
    Meeting Abstract

    Schuster, S. J.; Huw, L. Y.; Bolen, C. R.; Assouline, S. E.; Bartlett, N. L.; Budde, L. E.; Matasar, M. J.; Koeppen, H.; Piccione, E. C.; Wilson, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Izquierdo, A. R.; Martin, E. M. D.; Garcia-Sancho, A. M.; Sandoval-Sus, J. D.; Tilly, H.; Vandenberghe, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors
    Journal Article

    Salz, T.; Zabor, E. C.; Brown, P. D. N.; Dalton, S. O.; Raghunathan, N. J.; Matasar, M. J.; Steingart, R.; Hjalgrim, H.; Specht, L.; Vickers, A. J.; more...
    Acta Oncologica (2022)

    Fulltext@MSK | Save
  • A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Journal Article

    Qualls, D.; Lam, H. Y.; Whiting, K.; Kumar, A.; Matasar, M.; Owens, C.; Nichols, C.; Espeleta, J. A.; Qiu, A.; Subzwari, S.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Land(mark) ahoy: PFS24 in relapsed/refractory diffuse large B-cell lymphoma
    Editorial

    Matasar, M.
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • PI3K inhibitors in haematological malignancies
    Correspondence

    Matasar, M. J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma
    Meeting Abstract

    Dahi, P. B.; Geyer, A.; Kenny, S.; Flynn, J.; Devlin, S. M.; Ruiz, J. D.; Lahoud, O. B.; Matasar, M. J.; Moskowitz, C. H.; Perales, M. A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study
    Journal Article

    Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save